TRLV // Trulieve Cannabis Corp. Subordinate Voting Shares
ANR <GO> NYSE RQD COCKPIT → CIK 0001754195 ↗ Health Care • Medicinal Chemicals and Botanical Products
$10.60 ▼ -0.02
(-0.19%)
MKT CAP: $2.04B • VOL: 1.03M
52W L $5 52W H $13
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$9
MEDIAN
$12
MEAN
$12
HIGH
$14
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TRLV TAPE
TRLV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $12.83 | $12.19 | 2025-02-14 | $9.65 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $13.36 | $12.51 | 2025-02-06 | $9.96 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $12.08 | $11.66 | 2025-01-29 | $10.18 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $10.81 | — | 2025-01-17 | $10.39 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $9.33 | $10.07 | 2025-01-09 | $9.43 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $12.61 | $11.02 | 2024-12-18 | $9.22 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $10.28 | $10.71 | 2024-12-04 | $9.86 | -4.3% | 48% | C |